MedTrace Logo

Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs

NCT00560781 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2014-02-26

No results posted yet for this study

Summary

This study will test the therapeutic potential of augmenting a stable SSRI regimen with the neurosteroid pregnenolone to reduce cognitive symptoms and PTSD symptoms in patients diagnosed with PTSD.

Conditions

  • Stress Disorders, Post-Traumatic

Interventions

DRUG

Pregnenolone or Placebo

Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID

Sponsors & Collaborators

  • Durham VA Medical Center

    lead FED

Principal Investigators

  • Christine E Marx, MD MA · Durham VAMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-04-30
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00560781 on ClinicalTrials.gov